Anti-Aβ antibody target engagement: a response to Siemers et al

Andrew D Watt; Gabriela A N Crespi; Russell A Down; David B Ascher; Adam Gunn; Keyla A Perez; Catriona A McLean; Victor L Villemagne; Michael W Parker; Kevin J Barnham; Luke A Miles

doi:10.1007/s00401-014-1333-8

Anti-Aβ antibody target engagement: a response to Siemers et al

Andrew D Watt, Gabriela A N Crespi, Russell A Down, David B Ascher, Adam Gunn, Keyla A Perez, Catriona A McLean, Victor L Villemagne, Michael W Parker, Kevin J Barnham, Luke A Miles

Research output: Contribution to journal › Comment/debate › peer-review

3 Citations (Scopus)

Abstract

We have read with interest the commentary by Siemers et al. [28] regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.

Original language	English
Pages (from-to)	611-614
Number of pages	4
Journal	Acta Neuropathologica
Volume	128
Issue number	4
DOIs	https://doi.org/10.1007/s00401-014-1333-8
Publication status	Published - Oct 2014
Externally published	Yes

Access to Document

10.1007/s00401-014-1333-8

https://rdcu.be/eyheNLicence: Other

Cite this

@article{ac66d783db374259a4b5c53f4c5a42dd,

title = "Anti-Aβ antibody target engagement: a response to Siemers et al",

abstract = "We have read with interest the commentary by Siemers et al. [28] regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.",

author = "Watt, {Andrew D} and Crespi, {Gabriela A N} and Down, {Russell A} and Ascher, {David B} and Adam Gunn and Perez, {Keyla A} and McLean, {Catriona A} and Villemagne, {Victor L} and Parker, {Michael W} and Barnham, {Kevin J} and Miles, {Luke A}",

year = "2014",

month = oct,

doi = "10.1007/s00401-014-1333-8",

language = "English",

volume = "128",

pages = "611--614",

journal = "Acta Neuropathologica",

issn = "0001-6322",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - Anti-Aβ antibody target engagement

T2 - a response to Siemers et al

AU - Watt, Andrew D

AU - Crespi, Gabriela A N

AU - Down, Russell A

AU - Ascher, David B

AU - Gunn, Adam

AU - Perez, Keyla A

AU - McLean, Catriona A

AU - Villemagne, Victor L

AU - Parker, Michael W

AU - Barnham, Kevin J

AU - Miles, Luke A

PY - 2014/10

Y1 - 2014/10

N2 - We have read with interest the commentary by Siemers et al. [28] regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.

AB - We have read with interest the commentary by Siemers et al. [28] regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.

UR - http://www.scopus.com/inward/record.url?scp=84939893377&partnerID=8YFLogxK

U2 - 10.1007/s00401-014-1333-8

DO - 10.1007/s00401-014-1333-8

M3 - Comment/debate

C2 - 25120193

SN - 0001-6322

VL - 128

SP - 611

EP - 614

JO - Acta Neuropathologica

JF - Acta Neuropathologica

IS - 4

ER -

Anti-Aβ antibody target engagement: a response to Siemers et al

Abstract

Access to Document

Other files and links

Fingerprint

Cite this